P&K Skin Clinical Research Center Reports 6.2 Billion KRW Operating Profit in Q3 Cumulative, "45% Increase Year-on-Year"

[Asia Economy Reporter Hyunseok Yoo] P&K Skin Clinical Research Center (P&K), a skin human application testing institution, announced on the 16th that it recorded cumulative sales of 11.3 billion KRW, operating profit of 6.2 billion KRW, and net profit of 5.7 billion KRW for the third quarter. These represent increases of 31%, 45%, and 39% respectively compared to the same period last year.

In just three quarters, the company has already achieved 90% of the total sales of the previous year. The company explained that operating profit and net profit have already exceeded last year's figures.

For the third quarter alone, sales reached 3.5 billion KRW, operating profit 1.8 billion KRW, and net profit 1.7 billion KRW, marking increases of 16%, 32%, and 31% respectively compared to the same period last year.

CEO Lee Hae-kwang stated, “This year’s performance growth was driven by the expansion of orders in the cosmetics sector, led by cosmeceuticals, and an increased proportion of large corporations," adding, "we expect this trend to continue into the remaining fourth quarter.”

He added, “The average annual growth rate of sales over the past five years was 28%, and the average operating profit margin reached 50%. We believe that growth will continue not only this year but also in the future. The secret to this growth and profitability lies in leading trends through continuous development of new testing methods, creating high added value accordingly, and proactive investment.” He continued, “We will respond to market expectations with greater growth through the establishment of a new branch in the first quarter of next year and the establishment of a Chinese corporation in the second half of the year.”

This content was produced with the assistance of AI translation services.